

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 June 2022 (02.06.2022)



(10) International Publication Number
WO 2022/115611 A1

(51) International Patent Classification:

C07K 14/705 (2006.01) A61K 38/17 (2006.01)
C07K 14/715 (2006.01) C12N 5/0783 (2010.01)
C07K 14/54 (2006.01)

(21) International Application Number:

PCT/US2021/060833

(22) International Filing Date:

24 November 2021 (24.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/118,008 25 November 2020 (25.11.2020) US

(71) Applicant: CATAMARAN BIO, INC. [US/US]; 245 First Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: RICHARDSON, Celeste; 199 Wolcott Road, Brookline, Massachusetts 02467 (US). BARRON, Luke; 2130 Massachusetts Ave., Cambridge, Massachusetts

02140 (US). STORER, James Alexander; 10 Mammola Way, Medford, Massachusetts 02155 (US).

(74) Agent: REITER, Tiffany; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: CELLULAR THERAPEUTICS ENGINEERED WITH SIGNAL MODULATORS AND METHODS OF USE THEREOF




FIG. 1

(57) Abstract: The present disclosure is directed to an engineered protein (e.g., a chimeric protein) comprising one or more of an extracellular domain, a transmembrane domain and/or an intracellular domain, which are capable of binding a negative signal and functioning as a sink, dominant negative, or signal inverter for the negative signal. The disclosure is further directed to methods of generating a modified cell expressing one or more of the engineered proteins (e.g., chimeric proteins), and methods of using the modified cells in treating a disease or a condition in a subject in need thereof.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*